Seven Bridges

Seven Bridges, originally founded as a biomedical data company specializing in bioinformatics, has pivoted to focus on specialty pharmacy services under its new subsidiary Seven Bridges Specialty.

Reviewed by 7wData
Share Email

On this page

Profile

Provides specialty pharmacy services and technology solutions to improve patient access to life-changing therapies.

Seven Bridges, originally founded as a biomedical data company specializing in bioinformatics, has pivoted to focus on specialty pharmacy services under its new subsidiary Seven Bridges Specialty. The company appointed Steve Granzyk, a veteran in specialty pharmacy and biotech, as President and CEO in January 2025. Granzyk, previously at AcariaHealth, brings expertise in cell and gene therapy, patient assistance programs, and rare disease solutions.

Seven Bridges Specialty aims to modernize patient care in niche markets like rare diseases and cell therapies, leveraging technology to streamline pharmaceutical partnerships and patient access. The company is backed by 653 Investment Partners, which supports its growth in healthcare and technology sectors. While its earlier genomics division launched initiatives like the Unified Patient Network (UPN) to advance precision medicine, the current focus is on transforming specialty pharmacy services with a patient-centric approach.

Track Seven Bridges and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Pharmaceutical companies requiring specialty pharmacy support
  • Healthcare providers managing rare disease treatments
  • Biotech firms developing cell and gene therapies
  • Patient assistance programs and REMS administrators

Strengths and what to watch

Strengths

  • Leadership with deep specialty pharmacy expertise, including CEO Steve Granzyk’s track record in orphan drug markets
  • Backing by 653 Investment Partners, providing strategic and financial support
  • Focus on high-growth niches like rare diseases and cell/gene therapies

Watch for

  • Pivot from genomics to specialty pharmacy may alienate former bioinformatics clients
  • Dependence on pharmaceutical partnerships for revenue growth
  • Regulatory complexities in rare disease and gene therapy markets

Key Information

Founded
2009

Frequently Asked Questions

What does Seven Bridges do now?

Seven Bridges provides specialty pharmacy services and technology solutions, focusing on improving patient access to therapies for rare diseases and cell/gene treatments. The company pivoted from bioinformatics to pharmacy under CEO Steve Granzyk, leveraging partnerships and tech to streamline pharmaceutical collaborations and patient care programs.

Who is the CEO of Seven Bridges?

Steve Granzyk became President and CEO in January 2025. A specialty pharmacy veteran, he previously led AcariaHealth and brings expertise in rare disease treatments, patient assistance programs, and cell/gene therapy markets to drive Seven Bridges' pharmacy-focused transformation.

What makes Seven Bridges unique in specialty pharmacy?

Seven Bridges combines deep rare disease expertise with technology-driven patient access solutions. Backed by 653 Investment Partners, it focuses on niche markets like gene therapies, offering pharmaceutical partners specialized support through its leadership's 20+ years in orphan drug commercialization and patient assistance programs.

How does Seven Bridges support rare disease patients?

The company develops patient-centric programs for rare disease therapies, including assistance programs and REMS administration. Its technology streamlines access to specialized treatments while its leadership's biotech experience ensures tailored support for complex conditions like genetic disorders and cell therapies.

What happened to Seven Bridges' genomics work?

While Seven Bridges previously offered bioinformatics services like its Unified Patient Network for precision medicine, it has shifted focus to specialty pharmacy under new leadership. The genomics division's initiatives continue but are no longer the company's primary business direction.

Who invests in Seven Bridges?

653 Investment Partners backs Seven Bridges, providing strategic and financial support for its specialty pharmacy growth. This partnership enables the company to expand its technology-enabled services in rare disease and gene therapy markets while maintaining pharmaceutical industry collaborations.

Sources

  1. www.prnewswire.com — CEO appointment and company pivot to specialty pharmacy
  2. www.prnewswire.com — UPN initiative and genomics division history
  3. www.sevenbridges.com — Company description and bioinformatics focus
  4. www.sevenbridges.com — Technical capabilities and cloud partnerships